Sorafenib exhibits lower toxicity and comparable efficacy to sunitinib as a first-line treatment for metastatic renal cell carcinoma: A systematic review and meta-analysis

BACKGROUND: To assess the safety and efficacy of sorafenib and sunitinib as first-line treatments for metastatic renal cell carcinoma (mRCC), to provide evidence-based support for clinical decision-making regarding rational drug use. METHODS: Until May 10, 2023, a comprehensive search was conducted...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Dailong, Wan, Sha, Li, Wanqiang, Cheng, Chunlai, Xu, Lu, Gu, Peng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
5700
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10489528/
https://www.ncbi.nlm.nih.gov/pubmed/37682147
http://dx.doi.org/10.1097/MD.0000000000034983

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10489528/
https://www.ncbi.nlm.nih.gov/pubmed/37682147
http://dx.doi.org/10.1097/MD.0000000000034983

Ejemplares similares